| First Author | Bolden JE | Year | 2018 |
| Journal | J Leukoc Biol | Volume | 104 |
| Issue | 1 | Pages | 123-133 |
| PubMed ID | 29645346 | Mgi Jnum | J:265358 |
| Mgi Id | MGI:6188415 | Doi | 10.1002/JLB.1MA1217-475R |
| Citation | Bolden JE, et al. (2018) Identification of a Siglec-F+ granulocyte-macrophage progenitor. J Leukoc Biol 104(1):123-133 |
| abstractText | In recent years multi-parameter flow cytometry has enabled identification of cells at major stages in myeloid development; from pluripotent hematopoietic stem cells, through populations with increasingly limited developmental potential (common myeloid progenitors and granulocyte-macrophage progenitors), to terminally differentiated mature cells. Myeloid progenitors are heterogeneous, and the surface markers that define transition states from progenitors to mature cells are poorly characterized. Siglec-F is a surface glycoprotein frequently used in combination with IL-5 receptor alpha (IL5Ralpha) for the identification of murine eosinophils. Here, we describe a CD11b(+) Siglec-F+ IL5Ralpha- myeloid population in the bone marrow of C57BL/6 mice. The CD11b(+) Siglec-F+ IL5Ralpha- cells are retained in eosinophil deficient PHIL mice, and are not expanded upon overexpression of IL-5, indicating that they are upstream or independent of the eosinophil lineage. We show these cells to have GMP-like developmental potential in vitro and in vivo, and to be transcriptionally distinct from the classically described GMP population. The CD11b+ Siglec-F+ IL5Ralpha- population expands in the bone marrow of Myb mutant mice, which is potentially due to negative transcriptional regulation of Siglec-F by Myb. Lastly, we show that the role of Siglec-F may be, at least in part, to regulate GMP viability. |
